Literature DB >> 25366875

Investigation of the mechanisms mediating MDMA "Ecstasy"-induced increases in cerebro-cortical perfusion determined by btASL MRI.

J Rouine1, M E Kelly, C Jennings-Murphy, P Duffy, I Gorman, S Gormley, C M Kerskens, Andrew Harkin.   

Abstract

RATIONALE: Acute administration of the recreational drug of abuse 3,4-methylenedioxymethamphetamine (MDMA; Ecstasy) has previously been shown to increase cerebro-cortical perfusion as determined by bolus-tracking arterial spin labelling (btASL) MRI.
OBJECTIVES: The purpose of the current study was to assess the mechanisms mediating these changes following systemic administration of MDMA to rats.
METHODS: Pharmacological manipulation of serotonergic, dopaminergic and nitrergic transmission was carried out to determine the mechanism of action of MDMA-induced increases in cortical perfusion using btASL MRI.
RESULTS: Fenfluramine (10 mg/kg), like MDMA (20 mg/kg), increased cortical perfusion. Increased cortical perfusion was not obtained with the 5-HT2 receptor agonist 2,5-dimethoxy-4-iodophenyl-aminopropane hydrochloride (DOI) (1 mg/kg). Depletion of central 5-HT following systemic administration of the tryptophan hydroxylase inhibitor para-chlorophenylalanine (pCPA) produced effects similar to those observed with MDMA. Pre-treatment with the 5-HT receptor antagonist metergoline (4 mg/kg) or with the 5-HT reuptake inhibitor citalopram (30 mg/kg), however, failed to produce any effect alone or influence the response to MDMA. Pre-treatment with the dopamine D1 receptor antagonist SCH 23390 (1 mg/kg) failed to influence the changes in cortical perfusion obtained with MDMA. Treatment with the neuronal nitric oxide (NO) synthase inhibitor 7-nitroindazole (7-NI) (25 mg/kg) provoked no change in cerebral perfusion alone yet attenuated the MDMA-related increase in cortical perfusion.
CONCLUSIONS: Cortical 5-HT depletion is associated with increases in perfusion although this mechanism alone does not account for MDMA-related changes. A role for NO, a key regulator of cerebrovascular perfusion, is implicated in MDMA-induced increases in cortical perfusion.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25366875     DOI: 10.1007/s00213-014-3790-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  74 in total

1.  MDMA induced dopamine release in vivo: role of endogenous serotonin.

Authors:  S Koch; M P Galloway
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate.

Authors:  B Gough; S F Ali; W Slikker; R R Holson
Journal:  Pharmacol Biochem Behav       Date:  1991-07       Impact factor: 3.533

3.  Pharmacologic neuroimaging of the ontogeny of dopamine receptor function.

Authors:  Y Iris Chen; Ji-Kyung Choi; Haibo Xu; Jiaqian Ren; Susan L Andersen; Bruce G Jenkins
Journal:  Dev Neurosci       Date:  2010-06-03       Impact factor: 2.984

4.  Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate.

Authors:  W L Nixdorf; K B Burrows; G A Gudelsky; B K Yamamoto
Journal:  J Neurochem       Date:  2001-04       Impact factor: 5.372

5.  The dorsal facial area of the medulla in cats: inhibitory action of serotonin on glutamate release in regulating common carotid blood flow.

Authors:  H T Li; W Y Chen; L Liu; C S Yang; F C Cheng; C Y Chai; J S Kuo
Journal:  Neurosci Lett       Date:  1996-06-07       Impact factor: 3.046

Review 6.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

7.  Reduced efficacy of fluoxetine following MDMA ("Ecstasy")-induced serotonin loss in rats.

Authors:  Sarah Durkin; Alison Prendergast; Andrew Harkin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-09-13       Impact factor: 5.067

8.  Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin.

Authors:  M Shankaran; G A Gudelsky
Journal:  Pharmacol Biochem Behav       Date:  1998-12       Impact factor: 3.533

9.  5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa.

Authors:  C J Schmidt; V L Taylor; G M Abbate; T R Nieduzak
Journal:  J Pharmacol Exp Ther       Date:  1991-01       Impact factor: 4.030

10.  Methamphetamine and 3,4-methylenedioxymethamphetamine interact with central nicotinic receptors and induce their up-regulation.

Authors:  Sara Garcia-Ratés; Jordi Camarasa; Elena Escubedo; David Pubill
Journal:  Toxicol Appl Pharmacol       Date:  2007-05-26       Impact factor: 4.219

View more
  1 in total

1.  Distribution of temperature changes and neurovascular coupling in rat brain following 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") exposure.

Authors:  Daniel Coman; Basavaraju G Sanganahalli; Lihong Jiang; Fahmeed Hyder; Kevin L Behar
Journal:  NMR Biomed       Date:  2015-08-19       Impact factor: 4.044

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.